je.st
news
Tag: biotech
Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference
2014-09-20 00:55:19| Biotech - Topix.net
Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Bruce Given, M.D., Arrowhead's chief operating officer, will present at BioCentury's 21st Annual NewsMakers in the Biotech Industry conference on September 26, 2014 at 10:30 a.m. EDT in New York. Investors may access a live and archived audio webcast on the Company's website at http://ir.arrowhedresearch.com/events.cfm .
Tags: present
industry
conference
biotech
Food, biotech groups give $1M against Measure 92
2014-09-19 11:14:30| Food - Topix.net
As expected, many of the nation's largest food companies are weighing in with contributions against Measure 92, which would require labeling of genetically modified food products in Oregon. So far the No on 92 campaign has raised more than $1 million, about $800,000 of which is still on hand, according to the Oregon Elections Division Orestar system.
Tags: give
groups
food
measure
Oncolytics Biotech Receives Buy Rating from Paradigm Capital
2014-09-17 19:36:48| Biotech - Topix.net
's stock had its "buy" rating reissued by investment analysts at Paradigm Capital in a note issued to investors on Wednesday. They currently have a C$8.00 price objective on the stock, down from their previous price objective of C$10.00.
Tags: buy
rating
capital
receives
How cost pressures under Obamacare can be a boon to the biotech industry
2014-09-16 22:22:54| Biotech - Topix.net
President Barack Obama's signature Affordable Care Act has spurred plenty of attacks on the pharmaceutical industry, but it has also created opportunities, according to Flagship Ventures partner Harry Wilcox. The recent launches of drugs with high up-front costs have revived the longstanding debate over how much new medicines ought to cost.
Cost a focus as GSK takes lead in new wave of biotech lung drugs
2014-09-08 18:10:50| Biotech - Topix.net
Cost-effectiveness is seen as a challenge for a new group of biotech lung drugs that have produced promising results in clinical tests, of which the first is likely to be launched next year by GlaxoSmithKline. Rival firms are racing to develop similar injectable drugs for patients with severe asthma, who do not respond adequately to traditional inhalers, in pursuit of a new market that analysts believe may be worth around $7.5 billion in annual sales.
Sites : [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] next »